---
title: "Celestial Biolabs Ltd (CELESTIAL) — Share Price, Financials & Analysis"
symbol: "CELESTIAL"
company: "Celestial Biolabs Ltd"
canonical: "https://tapetide.com/stocks/CELESTIAL"
isin: "INE221I01017"
nse_symbol: "CELESTIAL"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:14:53.110Z"
---

# Celestial Biolabs Ltd (CELESTIAL)

Canonical page: https://tapetide.com/stocks/CELESTIAL

## Company

- **NSE Symbol:** CELESTIAL
- **ISIN:** INE221I01017
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2007-07-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** celestialbiolabs.com

## About

Celestial Biolabs is engaged in activities of manufacturingof Ayurvedic products and Trading of Feed suppliments.

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- Contingent liabilities of Rs.1.29 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 7,966 days.

## Growth Rates

| Metric | 1Y |
| --- | --- |
| net income growth | 33% |
| revenue growth | -26% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.06 | 0.06 | 0.04 | 0.03 | 0.04 | 0.02 | 0.04 | 0.04 |
| Expenses | 0.33 | 0.15 | 0.11 | 0.18 | 0.27 | 0.11 | 0.07 | 0.07 |
| Operating Profit | -0.27 | -0.09 | -0.07 | -0.15 | -0.23 | -0.09 | -0.03 | -0.03 |
| OPM % | -450 | -150 | -175 | -500 | -575 | -450 | -75 | -75 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | -0.28 | -0.1 | -0.08 | -0.16 | -0.25 | -0.1 | -0.04 | -0.04 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -0.28 | -0.1 | -0.08 | -0.15 | -0.24 | -0.1 | -0.03 | -0.04 |
| EPS in Rs | -0.12 | -0.04 | -0.04 | -0.07 | -0.11 | -0.04 | -0.01 | -0.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | TTM |
| --- | --- | --- | --- |
| Sales | 0.15 | 0.17 | 0.14 |
| Expenses | 0.49 | 0.71 | 0.52 |
| Operating Profit | -0.34 | -0.54 | -0.38 |
| OPM % | -226.67 | -317.65 | -271.43 |
| Other Income | 0 | 0 | 0 |
| Interest | 0.04 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.04 |
| Profit before tax | -0.41 | -0.58 | -0.43 |
| Tax % | 0 | 0 | — |
| Net Profit | -0.41 | -0.58 | -0.41 |
| EPS in Rs | -0.18 | -0.26 | -0.18 |
| Dividend Payout % | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Sep 2023 |
| --- | --- | --- | --- |
| Equity Capital | 22.59 | 22.59 | 22.59 |
| Reserves | -19.24 | -19.81 | -19.94 |
| Borrowings | 11.54 | 12.03 | 12.04 |
| Other Liabilities | 2.29 | 2.43 | 2.49 |
| Total Liabilities | 17.18 | 17.24 | 17.18 |
| Fixed Assets | 0.1 | 0.08 | 0.06 |
| CWIP | 12.82 | 12.82 | 12.82 |
| Investments | 0 | 0 | 0 |
| Other Assets | 4.26 | 4.34 | 4.3 |
| Total Assets | 17.18 | 17.24 | 17.18 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 |
| --- | --- | --- |
| Cash from Operating Activity | -0.28 | -0.36 |
| Cash from Investing Activity | 0 | 0 |
| Cash from Financing Activity | 0.26 | 0.38 |
| Net Cash Flow | -0.02 | 0.02 |
| Free Cash Flow | -0.28 | -0.37 |
| CFO/OP | 82 | 67 |

### Ratios

| Item | Mar 2022 | Mar 2023 |
| --- | --- | --- |
| Debtor Days | 9319.67 | 7965.59 |
| Inventory Days | 86.9 | 99.55 |
| Days Payable | 451.9 | 1161.36 |
| Cash Conversion Cycle | 8954.67 | 6903.77 |
| Working Capital Days | -2628 | -2512.06 |
| ROCE % | — | -3.84 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 37.31% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% |
| Public | 62.69% | 73.93% | 73.93% | 73.93% | 73.93% | 73.93% | 73.92% | 73.92% |
| No. of Shareholders | 10336 | 12167 | 13161 | 12575 | 12588 | 12558 | 12534 | 12523 |

### Quarterly

| Category | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% | 26.07% |
| Public | 73.93% | 73.93% | 73.93% | 73.93% | 73.93% | 73.93% | 73.92% | 73.92% | 73.92% | 73.93% | 73.92% | 73.92% |
| No. of Shareholders | 12579 | 12572 | 12564 | 12558 | 12553 | 12548 | 12539 | 12534 | 12533 | 12530 | 12530 | 12523 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 32.58 | Buy |
| EMA (10) | 33.03 | Sell |
| SMA (20) | 34.59 | Sell |
| EMA (20) | 33.92 | Sell |
| SMA (50) | 35.71 | Sell |
| EMA (50) | 35.75 | Sell |
| SMA (100) | 38.38 | Sell |
| EMA (100) | 38.57 | Sell |
| SMA (200) | 45.14 | Sell |
| EMA (200) | 43.23 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 42.6 | Neutral |
| MACD (12,26,9) | -1.15 | Sell |
| Stochastic (14,3,3) | 35.01 | Neutral |
| ADX (14) | 21.77 | Neutral |
| Williams %R (14) | -53.4 | Neutral |
| ATR (14) | 1.96 | High Volatility |
| ROC (12) | -2.11 | Sell |
| Stoch RSI (14) | 93.51 | Sell |
| UO (7,14,28) | 55.82 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Q3 loss with revenue down 70.5% QoQ; MoU for ₹800 crore Sankalp EPC; proposed 40% HETL acquisition. | [Results Performance Update Presentation - Q3 FY 2025-26 Results Update 9 Feb - Q3 loss with revenue down 70.5% QoQ; MoU for ₹800 crore Sankalp EPC; proposed 40% HETL acquisition.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/faff2fe7-03c5-4dbb-a0df-42a00c393f67.pdf) |
| 7 Feb - Approved Q3/9M FY2025-26 unaudited results (31 Dec 2025); Q3 revenue ₹448.00L; appointed K J Kabra & Associates. | [Board Meeting Outcome for VL E Governance & IT Solutions Limited Has informed Regarding Outcome Of Board Meeting Held On February 07, 2026. 7 Feb - Approved Q3/9M FY2025-26 unaudited results (31 Dec 2025); Q3 revenue ₹448.00L; appointed K J Kabra & Associates.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/399ded54-40ab-44c3-ae37-9a3dae77531f.pdf) |
| 3 Feb - Board meeting on 7 Feb 2026 to approve unaudited Q3 and nine-month results ended 31 Dec 2025. | [Board Meeting Intimation for Considering And Approving The Un-Audited Standalone Financial Results Of The Company For The Quarter Ended 31St December, 2025 3 Feb - Board meeting on 7 Feb 2026 to approve unaudited Q3 and nine-month results ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7275465b-a0f5-40af-8914-4861c07ce2b3.pdf) |
| 24 Feb - No undisclosed information; attributes price movement to market forces; confirms Listing Regulations compliance. | [Clarification On Price Movement 24 Feb - No undisclosed information; attributes price movement to market forces; confirms Listing Regulations compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c4159caf-b701-4994-a103-e2b4c1b8a54a.pdf) |
| 16 Oct 2024 - Members of the Exchange are hereby informed about the delisting of equity shares of Celestial Biolabs Limited w.e.f. October 17, 2024 in terms of Rule … | [Delisting 16 Oct 2024 - Members of the Exchange are hereby informed about the delisting of equity shares of Celestial Biolabs Limited w.e.f. October 17, 2024 in terms of Rule …](https://www.nseindia.com/get-quotes/equity?symbol=CELESTIAL) |
| 12 Feb - CARE report: Rs.630cr issue; Rs.400.99cr subscribed; Rs.114.31cr received; undersubscription and sharp share-price decline noted (Dec 31, 2025). | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report 12 Feb - CARE report: Rs.630cr issue; Rs.400.99cr subscribed; Rs.114.31cr received; undersubscription and sharp share-price decline noted (Dec 31, 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57271d49-a6e6-40e3-8f50-0ec17bd56150.pdf) |
| — | [Closure of Trading Window 26 Dec 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ae89858-b6f5-4b12-bd3f-24da63489e56.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2013 from nse](https://archives.nseindia.com/annual_reports/AR_2228_CELESTIAL_2012_2013_07102013145302.zip) |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_CELESTIAL_2010_2011_15062012120215.zip) |
| from nse | [Annual Report 2010 from nse](https://archives.nseindia.com/annual_reports/AR_CELESTIAL_2009_2010_08042011101007.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/35384650-3d26-42b4-ac31-94393d77da0e.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9af50518-f597-4e3e-b1a8-dabb24a7bcf4.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport//5328710318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport//5328710317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport//5328710316.pdf) |
| from bse | [Annual Report 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport//5328710315.pdf) |
| from bse | [Annual Report 2014 from bse](https://www.bseindia.com/bseplus/AnnualReport//5328710314.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:14:53.110Z.